与人乳头瘤病毒 (HPV) 相关的口咽癌 (OPC) 的发病率在全球范围内不断增加。 HPV 疫苗已显示出对预防男性和女性疾病的功效。因此，需要制定具有成本效益的HPV疫苗策略来预防HPV相关的OPC。这项荟萃分析旨在使用增量成本效益比的全球平均值与男孩延长疫苗和仅女孩之间的 HPV 疫苗接种策略的支付意愿阈值和增量净效益 (INB) 进行比较来评估成本效益。这些建议对于尚未在国家计划中实施通用 HPV 疫苗的国家（例如台湾）非常有用。通过 Cochrane 图书馆确定了评估 HPV 疫苗接种策略在预防 OPC 方面的成本效益的研究，其中包括男女与仅女孩、EMBASE、PubMed、ScienceDirect 和 Web of Science 数据库于 2024 年 2 月 5 日进行，并使用随机效应模型对汇集的 INB 进行了荟萃分析。结果是 OPC 负担的有效测量。结果以美元（2024 年）表示。包括 15 种模型分析。所有研究都是在高收入国家进行的。每增加质量调整生命年，增量成本效益比的全球平均值为 39,553 美元（95% CI，27,008-66,641 美元），低于支付意愿阈值的全球平均值 65,473 美元（95% CI，52,138 美元） -83,755）。汇总 INB 为 9370 美元（95% CI，5046-13,695 美元；P < 0.001）有利于男孩接种扩展 HPV。与仅预防 OPC 负担的女孩相比，包括男孩在内的 HPV 疫苗接种策略具有成本效益。通过实施全民 HPV 疫苗接种计划，各国每位患者可以获得 9370 美元的额外货币福利。鉴于其与高收入国家的相关性，这项研究提供了可以帮助台湾政策制定者的重要见解。© 2024 中华民国牙科科学协会。 Elsevier B.V. 的出版服务

The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) is increasing worldwide. HPV vaccines have shown efficacy in preventing diseases in both males and females. Therefore, there is a need to develop cost-effective strategies for HPV vaccines to prevent HPV-related OPC. This meta-analysis aimed to evaluate cost-effectiveness using the global mean of incremental cost-effectiveness ratios compared to the willingness-to-pay threshold and incremental net benefits (INBs) of HPV vaccination strategies between boys' extension vaccine and girls only. These recommendations will be useful for countries that have not implemented universal HPV vaccines in national programs, such as Taiwan.Studies evaluating the cost-effectiveness of HPV vaccination strategies in the prevention of OPC that included both sexes versus girls only were identified through the Cochrane Library, EMBASE, PubMed, ScienceDirect, and Web of Science databases on February 05, 2024, and a meta-analysis of pooled INBs was performed using a random-effects model. The outcome was an effective measurement of the OPC burden. The results are represented in USD (2024).Fifteen model analyses were included. All the studies were conducted in high-income countries. The global mean of incremental cost-effectiveness ratio was $39,553 (95% CI, $27,008-66,641) per quality-adjusted life years gained, which was below the global mean of the willingness-to-pay threshold of $65,473 (95% CI, $52,138-83,755). Pooled INBs of $9370 (95% CI, $5046-13,695; P < 0.001) favored the extended HPV in boys.HPV vaccination strategies that include boys are cost-effective compared to those with girls only in preventing OPC burden. By implementing a universal HPV vaccination program, countries can receive $9370 in additional monetary benefits per patient. Given its relevance to high-income countries, this study offers key insights that can aid policymakers in Taiwan.© 2024 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.